MedPath

Proactive versus reactive inhibition in ADHD: Genetics, Neurobiology and pharmacology

Completed
Conditions
aandachtstekortstoornis
ADHD
10009841
Registration Number
NL-OMON41454
Lead Sponsor
niversitair Medisch Centrum Utrecht
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
80
Inclusion Criteria

Children diagnosed with ADHD according to DSM IV criteria
Age between 8-16
Willing to discontinue methylphenidate 48 hours before testing
IQ above 75

Exclusion Criteria

History of or present neurological disorder
One or more of the following comorbid disorders are diagnosed: generalized anxiety disorder, depression, tics, psychosis or autism
IQ below 75

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>The primary outcomes of this study are<br /><br>(1) Stop-associated ERP measures at baseline (N1 and P3) (objective 1.1)<br /><br>(2) Stop-associated fMRI measures at baseline (activitity in IFG an SFG)<br /><br>(objective 1.2)<br /><br>(3) DAT1 and COMT genotype (objective 1.3)</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>The secondary outcomes of this study are<br /><br>(1) Coherence of brain activity from EEG (objective 2.1)<br /><br>(2) Connectivity between IFG and SFG from RS-MRI (objective 2.2)</p><br>
© Copyright 2025. All Rights Reserved by MedPath